This page is part of the FHIR Specification (v1.1.0: STU 3 Ballot 1). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3 R2
This is a frozen snapshot of the FHIR specification created for the purpose of balloting the GAO implementation Guide. It includes draft changes that may be part of the future DSTU 2.1 release but further change is expected. Readers should focus solely on the GAO implementation content, and FHIR DSTU 2 for other purposes.
V3-substanceAdminSubstitution.xml

Raw XML (canonical form)
Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.
<ValueSet xmlns="http://hl7.org/fhir">
  <id value="v3-substanceAdminSubstitution"/>
  <meta>
    <lastUpdated value="2015-11-30T00:00:00.000+11:00"/>
    <profile value="http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p>Release Date: 2015-11-30</p>

      <p>OID for code system: 2.16.840.1.113883.5.1070</p>

      <h2>Description</h2>

      <p>
                  Identifies what sort of change is permitted or has occurred between
           the therapy that was ordered and the therapy that was/will be provided.
        <br/>

               
      </p>

      <hr/>

      <table class="grid">
 
        <tr>
          <td>
            <b>Level</b>
          </td>
          <td>
            <b>Code</b>
          </td>
          <td>
            <b>Display</b>
          </td>
          <td>
            <b>Definition</b>
          </td>
        </tr>
 
        <tr>
          <td>1</td>
          <td>
            <span style="color: grey">
              <i>(_ActSubstanceAdminSubstitutionCode)</i>
            </span>
          </td>
          <td>
            <a name="_ActSubstanceAdminSubstitutionCode"> </a>
          </td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product that may potentially have different ingredients, but having the same biological
               and therapeutic effects.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  E
            <a name="E"> </a>
          </td>
          <td>equivalent</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               bioequivalent and therapeutically equivalent product.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    EC
            <a name="EC"> </a>
          </td>
          <td>equivalent composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted with another product that
               is a:
            <br/>

                        
                           pharmaceutical alternative containing the same active ingredient
               but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
               strength, dosage form and route of administration
                        
                        
                           Examples: 
                        
            <br/>

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
               for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      BC
            <a name="BC"> </a>
          </td>
          <td>brand composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted between equivalent Brands
               but not Generics
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      G
            <a name="G"> </a>
          </td>
          <td>generic composition</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               equivalent Generics but not Brands
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    TE
            <a name="TE"> </a>
          </td>
          <td>therapeutic alternative</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product having the same therapeutic objective and safety profile.
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           ranitidine for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TB
            <a name="TB"> </a>
          </td>
          <td>therapeutic brand</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Brands but not Generics
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Zantac for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TG
            <a name="TG"> </a>
          </td>
          <td>therapeutic generic</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Generics but not Brands
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Ranitidine  for cimetidine
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  F
            <a name="F"> </a>
          </td>
          <td>formulary</td>
          <td>
                        
                           Description: This substitution was performed or is permitted
               based on formulary guidelines. 
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  N
            <a name="N"> </a>
          </td>
          <td>none</td>
          <td>
                        No substitution occurred or is permitted.
            <br/>

                     
          </td>
        </tr>

      </table>

    </div>
  </text>
  <url value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/>
  <version value="2015-11-30"/>
  <name value="v3 Code System substanceAdminSubstitution"/>
  <status value="active"/>
  <experimental value="false"/>
  <publisher value="HL7, Inc"/>
  <contact>
    <telecom>
      <system value="other"/>
      <value value="http://hl7.org"/>
    </telecom>
  </contact>
  <date value="2015-11-30"/>
  <description value=" Identifies what sort of change is permitted or has occurred between the therapy that
     was ordered and the therapy that was/will be provided."/>
  <codeSystem>
    <extension url="http://hl7.org/fhir/StructureDefinition/valueset-oid">
      <valueUri value="urn:oid:2.16.840.1.113883.5.1070"/>
    </extension>
    <system value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/>
    <caseSensitive value="true"/>
    <concept>
      <code value="_ActSubstanceAdminSubstitutionCode"/>
      <abstract value="true"/>
      <display value="ActSubstanceAdminSubstitutionCode"/>
      <definition value="Description: Substitution occurred or is permitted with another product that may potentially
         have different ingredients, but having the same biological and therapeutic effects."/>
      <concept>
        <code value="E"/>
        <abstract value="false"/>
        <display value="equivalent"/>
        <definition value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically
           equivalent product."/>
        <concept>
          <code value="EC"/>
          <abstract value="false"/>
          <display value="equivalent composition"/>
          <definition value="Description:                                                    Substitution occurred
             or is permitted with another product that is a:                                      
                            pharmaceutical alternative containing the same active ingredient but is
             formulated with different salt, ester                            pharmaceutical equivalent
             that has the same active ingredient, strength, dosage form and route of administration
                                                                                          Examples:
                                                                                                  
                                     Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin
             Stearate                                                           Pharmaceutical equivalent:
             Lisonpril for Zestril"/>
          <concept>
            <code value="BC"/>
            <abstract value="false"/>
            <display value="brand composition"/>
            <definition value="Description:                                                    Substitution occurred
               or is permitted between equivalent Brands but not Generics                           
                                         Examples:                                                  
                                            Zestril  for Prinivil                            Coumadin
               for Jantoven"/>
          </concept>
          <concept>
            <code value="G"/>
            <abstract value="false"/>
            <display value="generic composition"/>
            <definition value="Description: Substitution occurred or is permitted between equivalent Generics but not
               Brands                                                      Examples:                
                                                                              Lisnopril (Lupin Corp)
               for Lisnopril (Wockhardt Corp)"/>
          </concept>
        </concept>
        <concept>
          <code value="TE"/>
          <abstract value="false"/>
          <display value="therapeutic alternative"/>
          <definition value="Description: Substitution occurred or is permitted with another product having the same
             therapeutic objective and safety profile.                                            
                      Examples:                                                                   
                         ranitidine for Tagamet"/>
          <concept>
            <code value="TB"/>
            <abstract value="false"/>
            <display value="therapeutic brand"/>
            <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
               Brands but not Generics &gt;                            Examples:                    
                                                                          Zantac for Tagamet"/>
          </concept>
          <concept>
            <code value="TG"/>
            <abstract value="false"/>
            <display value="therapeutic generic"/>
            <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
               Generics but not Brands &gt;                            Examples:                    
                                                                          Ranitidine  for cimetidine"/>
          </concept>
        </concept>
      </concept>
      <concept>
        <code value="F"/>
        <abstract value="false"/>
        <display value="formulary"/>
        <definition value="Description: This substitution was performed or is permitted based on formulary guidelines."/>
      </concept>
      <concept>
        <code value="N"/>
        <abstract value="false"/>
        <display value="none"/>
        <definition value="No substitution occurred or is permitted."/>
      </concept>
    </concept>
  </codeSystem>
</ValueSet>
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.